Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease
A Randomized, Placebo-controlled, 2-arm Parallel-group Superiority Phase II Study of GLYCOpyrrolate for Moderate-to-severe Sialorrhea in PARkinson's Disease
Sponsor: Ottawa Hospital Research Institute
This PHASE2 trial investigates Parkinson's Disease and Sialorrhea and is currently ongoing. Ottawa Hospital Research Institute leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
May 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — May 2020 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ottawa Hospital Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Ottawa, Canada
- • Toronto, Canada